-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
PerkinElmer, Inc.
, a global leader in innovation for a healthier world, today announced the launch of two ready-to-use HTRF® and AlphaLISA® no-wash assay kits designed to quickly and easily perform in biopharmaceutical manufacturing processes Detection and quantification of CHO HCP impurities
.
Recombinant therapeutic proteins, such as monoclonal antibodies, some vaccines, and other biologics, must be free of residual host cell protein (HCP) impurities that prevent the immunogenicity of the drug or reduce potency, stability, or overall effectiveness
PerkinElmer's HTRF and AlphaLISA CHO HCP kits are the first ready-to-use homogeneous, no-wash assay kits on the market designed specifically for the detection and quantification of CHO HCP impurities
.
These off-the-shelf kits are designed to provide a simplified workflow, wider dynamic range, and higher sensitivity than traditional multi-step ELISA assays
"The ability to quickly and easily detect, quantify, and subsequently eliminate CHO HCP impurities in biopharmaceutical manufacturing processes has been a key challenge," said Alan Fletcher, senior vice president of life sciences at PerkinElmer
.
"These innovative HTRF and AlphaLISA The test kits are designed to make this critical step more effective and efficient in existing workflows and to aid in quality control and successful biotherapeutics
The addition of these assays further advances PerkinElmer's ability to provide scientists with end-to-end workflow solutions, from early stage drug discovery and development (including assays, cell lines, microplates and readers) to late stage R&D and High-content screening, image analysis and data management, automated liquid handling, and more